Hydrochlorothiazide (abbreviated HCTZ, HCT, or HZT), is a diuretic medication often used to treat high blood pressure and swelling due to fluid build up.Other uses include diabetes insipidus, renal tubular acidosis, and to decrease the risk of kidney stones in those with high calcium level in the urine. For high blood pressure it is often recommended as a first line treatment. HCTZ is taken by mouth and may be combined with other blood pressure medications as a single pill to increase the effectiveness.
Potential side effects include poor kidney function, electrolyte imbalances especially low blood potassium and less commonly low blood sodium, gout, high blood sugar, and feeling faint initially upon standing up. While allergies to HCTZ are reported to occur more often in those with allergies to sulfa drugs this association is not well supported. It may be used during pregnancy but is not a first line medication in this group.
It is in the thiazide medication class and acts by decreasing the kidneys' ability to retain water. This initially reduces blood volume, decreasing blood return to the heart and thus cardiac output. Long term, however, it is believed to lower peripheral vascular resistance.
Medical uses
Hydrochlorothiazide is frequently used for the treatment of hypertension, congestive heart failure, symptomatic edema, diabetes insipidus, renal tubular acidosis. It is also used for the prevention of kidney stones in those who have high levels of calcium in their urine.
Most of the research supporting the use of thiazide diuretics in hypertension was done using chlorthalidone, a different medication in the same class. Some more recent studies have suggested that chlorthalidone might be the more effective thiazide diuretic.
It is also sometimes used for treatment of hypoparathyroidism,hypercalciuria, Dent's disease, and Ménière's disease. For diabetes insipidus, the effect of thiazide diuretics is presumably mediated by a hypovolemia-induced increase in proximal sodium and water reabsorption, thereby diminishing water delivery to the ADH-sensitive sites in the collecting tubules and increasing the urine osmolality.
Thiazides are also used in the treatment of osteoporosis. Thiazides decrease mineral bone loss by promoting calcium retention in the kidney, and by directly stimulating osteoblast differentiation and bone mineral formation.
It may be given together with other antihypertensive agents in fixed-dose combination preparations, such as in losartan/hydrochlorothiazide.
Product Description:
Notice: This product is only suitable for laboratory use, or the use of animals. It can not be used directly on the human body
Product Name:Hydrochlorothiazide
Formula:C7H8ClN3O4S2
Molecular Weight:297.73
CAS No.:58-93-5
EINECS:200-403-3
Density:1.693 g/cm3
Melting Point:273 °C
Boiling Point:577 °C at 760 mmHg
Flash Point:577 °C at 760 mmHg
Appearance: White or almost white Crystalline powder
Specification:
| Contents | Specification | Results |
| Characteristics | White or almost white Crystalline powder | complies |
| Solubility | Very slightly soluble in water, slightly soluble in alcohol, Soluble in acetone and dilute solutions of alkalines hydroxides | complies |
| Coalition Band | 266°Cto270°C,with decomposition | complies |
| Identification | Meets the requirements | complies |
| Acidity or alkalinity | ≤0.4ml | 0.2ml |
| Chloride | ≤ 0.03% | < 0.01% |
| Selenium | < 0.003% | < 0.003% |
| Heavy metal | < 0.001% | < 0.001% |
| Residue on ignition | ≤0.1% | 0.03% |
Related Substances
a)Any peak
b)Sum of peak |
≤0.5%
≤1.0% |
0.28%
0.35% |
4-Amino-6-chloro-1.3-
-Benzenedisulfonamide | < 1% | 0.39% |
| Loss on drying | ≤ 0.5% | 0.04% |
| Organic volatile impurities | Meets the requirements | Complies |
| Assay | 98.0-102.0%(on the dried basis sub) | 99.58 % |
| Conclusion: It complies with the requirements of the USP32. | ||
Packaging & Shipping:
Packaging Detail: 25kgs/Paper Drum or as your require
MOQ: 1 Drum
Delivery Time: 3-7 days after receipt of payment
没有评论:
发表评论